Filtered By:
Condition: Diabetes
Nutrition: Vitamins

This page shows you your search results in order of date. This is page number 10.

Order by Relevance | Date

Total 434 results found since Jan 2013.

One-Year Clinical Outcome in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study
CONCLUSIONS: This study of Middle Eastern AF patients has reported high adherence to OACs. The use of OACs was associated with a lower risk for all-cause mortality. One-year rates of stroke and major bleeding events were comparable to those reported from other regions in the world.PMID:35462945 | PMC:PMC9020983 | DOI:10.1155/2022/4240999
Source: International Journal of Vascular Medicine - April 25, 2022 Category: Cardiology Authors: Ayman Hammoudeh Yousef Khader Ramzi Tabbalat Yahya Badaineh Nazih Kadri Haneen Shawer Eyas Al-Mousa Rasheed Ibdah Batool A Shawer Imad A Alhaddad Source Type: research

A Study of Srum Homocysteine Level in Ischaemic Stoke
CONCLUSION: The present study revealed that hyperhomocysteinemia appears to be an important risk factor for ischemic stroke. It is therefore important to use serum homocysteine as an important tool to investigate all cases of ischemic stroke and if serum homocysteine is elevated patient should be put on multivitamins containing vitamin B12, folic acid and pyridoxine to reduce serum homocysteine levels.PMID:35443421
Source: Atherosclerosis - April 21, 2022 Category: Cardiology Authors: Kaushik Paul Ramakrishna Mr Source Type: research

High-Dose Vitamin C Prevents Secondary Brain Damage After Stroke via Epigenetic Reprogramming of Neuroprotective Genes
AbstractVitamin C has recently been identified as an epigenetic regulator by activating ten-eleven translocases (TETs), enzymes involved in generating DNA hydroxymethylcytosine (5hmC). Currently, we investigated whether high-dose vitamin C promotes neuroprotection through epigenetic modulation of 5hmC, if there are sex-specific differences in outcome, and the therapeutic potential of vitamin C in stroke-related comorbidities in adult mice. Post-stroke treatment with ascorbate (reduced form), but not dehydroascorbate (oxidized form), increased TET3 activity and 5hmC levels and reduced infarct following focal ischemia. Hydro...
Source: Translational Stroke Research - March 20, 2022 Category: Neurology Source Type: research

Can I use DOAC in a patient with renal disease?
Case A 76-year-old man is diagnosed with non-valvular atrial fibrillation. His comorbid conditions are hypertension, diabetes complicated by neuropathy, and chronic kidney disease stage 3. His current medications include metformin, lisinopril, gabapentin, and aspirin. His most recent laboratories showed a creatinine 1.8, creatinine clearance (CrCl) 35 mL/min, hemoglobin 11g/dL, and international normalized ratio 1.0. His congestive heart failure, hypertension, age, diabetes, stroke, vascular disease, and sex (CHADSVASc) score is 4. Which medication should we use to prevent stroke in this patient?  Brief overview of the is...
Source: The Hospitalist - February 3, 2022 Category: Hospital Management Authors: Ronda Whitaker Tags: Renal & Genitourinary Source Type: research

Bleeding risk in patients with atrial fibrillation treated with combined anti-platelet and non-vitamin K antagonist oral anticoagulant therapy
CONCLUSIONS: The combination therapy group had higher incidences of any bleeding events compared to the monotherapy in patients with appropriate dosing. However, there was no difference in stroke/SE, and MACE. The bleeding risk in AF patients taking the combination of NOACs and APT should be carefully evaluated.PMID:35092194 | DOI:10.31083/j.rcm2301002
Source: Reviews in Cardiovascular Medicine - January 29, 2022 Category: Cardiology Authors: Dong Geum Shin Sunhwa Kim Yoo Ri Kim Source Type: research